AUS
NZ
UK
CA
USA
IND
Highlights:
ResMed’s revenue increased driven by performance across all major markets and product segments
Net profit recorded double-digit growth supported by expanded gross margins
Gross profit margin improved due to product mix and operational efficiencies
ResMed (ASX:RMD) operates in the healthcare sector, delivering digital health solutions and connected medical devices aimed at treating sleep-related and chronic respiratory conditions such as sleep apnea and chronic obstructive pulmonary disease. The company released its financial results for the third quarter of the financial year, showcasing broad-based growth across regions and product categories.
Revenue Growth Across Global Markets
The company reported a year-on-year rise in its total revenue. On a constant currency basis, the increase was slightly higher. This growth was attributed to demand across various geographies, with particularly strong contributions from the Americas region.
Sales in the US, Canada, and Latin America, excluding the residential care software business, increased compared to the same period last year. Similarly, performance in Europe, Asia, and other international markets also reflected a positive trend. In addition to hardware and devices, the company's residential care software segment also posted higher revenue compared to the prior corresponding quarter.
Margin Expansion and Operational Efficiency
ResMed noted improvements in both its reported and underlying gross profit margins. These gains were supported by enhanced manufacturing and logistics efficiency, as well as a favourable shift in the sales mix, particularly toward higher-margin products. The company stated that its gross margin performance reflected improvements across several operational areas and product lines.
The gross profit margin showed an uptick compared to the previous corresponding period. The underlying gross profit margin also expanded at a similar rate. The management attributed this improvement to streamlined production and shipping processes, along with the changing composition of products sold during the quarter.
Operating and Net Profit Growth
The company reported an increase in its operating profit over the same quarter last year. This improvement came alongside growth in its gross profit and controlled operational expenses. Higher revenue and improved margins translated into a strong performance in terms of operating profitability.
Net profit showed notable growth when compared with the previous year’s corresponding quarter. The underlying net profit also increased during the same period, reflecting the impact of both revenue growth and improved cost efficiencies. The net result was further supported by a favourable business environment and product demand dynamics across multiple global regions.
Segment and Product Line Performance
The revenue uplift was spread across the company’s core offerings. In addition to growth from the core sleep apnea and respiratory care segments, software-as-a-service solutions in the residential care space also contributed positively.
This segment, which supports care providers in home and community settings, demonstrated increased adoption and broader market penetration. The uplift in this area contributed further to the overall financial performance for the period.
Share Market Reaction
Following the release of the quarterly update, ResMed’s share price recorded an upward movement on the ASX. The response in the market came on the back of higher revenue, increased profitability, and margin improvements. The latest results reflect ongoing performance momentum in the healthcare and medtech space, particularly for companies involved in digital and cloud-based patient care solutions.
